-
Company Insights
Innovation and Patenting activity of The Children~s Place Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of The Children~s Place Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
NewLikelihood of Approval Analysis for Streptococcal Pneumonia
Overview How likely is it that the drugs in Streptococcal Pneumonia will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Streptococcal Pneumonia Overview Streptococcus pneumoniae, or pneumococcus, is a Gram-positive spherical bacteria,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Immune Globulin (Human) in Tachycardia (Tachyarrhythmias)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Immune Globulin (Human) in Tachycardia (Tachyarrhythmias) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Immune Globulin (Human) in Tachycardia (Tachyarrhythmias) Drug Details: Human Immunoglobulin...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cabozantinib S-malate in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cabozantinib S-malate in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cabozantinib S-malate in Gastric Cancer Drug Details: Cabozantinib s-malate (XL184, BMS907351,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Canakinumab in Pulmonary Sarcoidosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Canakinumab in Pulmonary Sarcoidosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Canakinumab in Pulmonary Sarcoidosis Drug Details: Canakinumab (Ilaris / Lasprona /...
-
Product Insights
Orthodontic Materials and Products Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Orthodontic Materials and Products Pipeline Market Report Overview Orthodontic materials and products are designed to correct teeth and jaws that are positioned improperly. The orthodontic materials and products pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials. Key...
-
Product Insights
Cytomegalovirus (HHV-5) Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Cytomegalovirus (HHV-5) Infections - Drugs In Development, 2023’, provides an overview of the Cytomegalovirus (HHV-5) Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cytomegalovirus (HHV-5) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Neurofibromatoses – Drugs In Development, 2023
Global Markets Direct’s, ‘Neurofibromatoses - Drugs In Development, 2023’, provides an overview of the Neurofibromatoses pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neurofibromatoses, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Squamous Non-Small Cell Lung Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Squamous Non-Small Cell Lung Cancer - Drugs In Development, 2023’, provides an overview of the Squamous Non-Small Cell Lung Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Squamous Non-Small Cell Lung Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...